BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

Denali is lifting the veil on the delivery technology it’s using to transport large molecules into the CNS, detailing a differentiated strategy for hijacking the transferrin receptor. The company revealed features of its large molecule...
BioCentury | May 29, 2020
Product Development

The pivotal role of real-world data in a pandemic

Real-world data is taking on a critical role in the age of COVID-19 drug development, where hasty authorizations are being made on limited datasets and natural history data is being collected in real time. Teams...
BioCentury | May 29, 2020
Product Development

Minerva’s schizophrenia miss casts doubt on approach to treating negative symptoms

Minerva’s Phase III miss in schizophrenia sent its shares down 72% on Friday, putting into doubt the future of the leading therapeutic candidate in development to treat the negative symptoms of schizophrenia -- an indication...
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio...
BioCentury | May 22, 2020
Emerging Company Profile

With $60M, Canaan-incubated Day One seizes on under-appreciated advances in pediatric cancers

Day One is using its $60 million series A round to acquire and develop cancer therapies that target biology shared by pediatric and adult cancers, capitalizing on growing understanding and clinical trial infrastructure to make...
BioCentury | May 16, 2020
Management Tracks

Bingham to lead U.K. push for a COVID-19 vaccine

The U.K. has picked longtime biotech investor Kate Bingham to chair the government’s Vaccine Taskforce, the latest example of the country deploying its industry expertise to combat COVID-19. Bingham will report directly to Prime Minister...
BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

Evox Therapeutics Ltd. said Paul Carter will succeed Edwin Moses as non-executive chairman. Carter was EVP, chief commercial officer of Gilead Sciences Inc. (NASDAQ:GILD). The exosome therapeutics company partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502;...
BioCentury | May 15, 2020
Product Development

Novartis R&D heads Bradner and Tsai see hard lessons and hope in coronavirus research

If industry had responded to the first SARS outbreak the way it is now, we would probably have drugs on hand to treat COVID-19. That sobering conclusion was evident, said NIBR’s Jay Bradner, when the...
BioCentury | May 14, 2020
Product Development

Collaborating against the challenges of COVID, a conversation with Novartis’ R&D heads

In the latest BioCentury This Week -- Special Report podcasts , Novartis R&D heads John Tsai and Jay Bradner discuss with BioCentury the challenges facing drug developers as they attempt to develop countermeasures against COVID-19, and...
BioCentury | May 12, 2020
Product Development

May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX

Genfit’s PPAR agonist fails to resolve NASH  Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) fell $10.88 (49%) to $11.22 in after-hours trading Monday after reporting that dual PPARα/δ agonist elafibranor missed the primary endpoint of the Phase III...
Items per page:
1 - 10 of 3730
BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

Denali is lifting the veil on the delivery technology it’s using to transport large molecules into the CNS, detailing a differentiated strategy for hijacking the transferrin receptor. The company revealed features of its large molecule...
BioCentury | May 29, 2020
Product Development

The pivotal role of real-world data in a pandemic

Real-world data is taking on a critical role in the age of COVID-19 drug development, where hasty authorizations are being made on limited datasets and natural history data is being collected in real time. Teams...
BioCentury | May 29, 2020
Product Development

Minerva’s schizophrenia miss casts doubt on approach to treating negative symptoms

Minerva’s Phase III miss in schizophrenia sent its shares down 72% on Friday, putting into doubt the future of the leading therapeutic candidate in development to treat the negative symptoms of schizophrenia -- an indication...
BioCentury | May 28, 2020
Emerging Company Profile

Atlas-built Q32 debuts with $46M, tissue-targeted complement platform, BMS mAb

Atlas-incubated Q32 emerged from stealth Wednesday with a complement platform aimed at modulating the innate immune system and a lead antibody program in-licensed from BMS targeting the adaptive immune system. Formed in 2018, Q32 Bio...
BioCentury | May 22, 2020
Emerging Company Profile

With $60M, Canaan-incubated Day One seizes on under-appreciated advances in pediatric cancers

Day One is using its $60 million series A round to acquire and develop cancer therapies that target biology shared by pediatric and adult cancers, capitalizing on growing understanding and clinical trial infrastructure to make...
BioCentury | May 16, 2020
Management Tracks

Bingham to lead U.K. push for a COVID-19 vaccine

The U.K. has picked longtime biotech investor Kate Bingham to chair the government’s Vaccine Taskforce, the latest example of the country deploying its industry expertise to combat COVID-19. Bingham will report directly to Prime Minister...
BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

Evox Therapeutics Ltd. said Paul Carter will succeed Edwin Moses as non-executive chairman. Carter was EVP, chief commercial officer of Gilead Sciences Inc. (NASDAQ:GILD). The exosome therapeutics company partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502;...
BioCentury | May 15, 2020
Product Development

Novartis R&D heads Bradner and Tsai see hard lessons and hope in coronavirus research

If industry had responded to the first SARS outbreak the way it is now, we would probably have drugs on hand to treat COVID-19. That sobering conclusion was evident, said NIBR’s Jay Bradner, when the...
BioCentury | May 14, 2020
Product Development

Collaborating against the challenges of COVID, a conversation with Novartis’ R&D heads

In the latest BioCentury This Week -- Special Report podcasts , Novartis R&D heads John Tsai and Jay Bradner discuss with BioCentury the challenges facing drug developers as they attempt to develop countermeasures against COVID-19, and...
BioCentury | May 12, 2020
Product Development

May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX

Genfit’s PPAR agonist fails to resolve NASH  Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) fell $10.88 (49%) to $11.22 in after-hours trading Monday after reporting that dual PPARα/δ agonist elafibranor missed the primary endpoint of the Phase III...
Items per page:
1 - 10 of 3730